GH1 and acromegaly: Furthermore, while a GH threshold of 2.5 μg/L was employed for the second key secondary endpoint, in accordance with guidance from the US Food and Drug Administration, in practice mean GH remained ≤1.0 μg/L in CAM2029-treated patients throughout the duration of the trial, in line with current guidelines for the treatment of acromegaly (7).